Last Updated: August 29, 2026

Claims for Patent: 12,599,610

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,599,610

Title:	Solid dosage formulations of an orexin receptor antagonist
Abstract:	The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.
Inventor(s):	Paul A. Harmon, Narayan Variankaval, Michael Lowinger, Chad David Brown, Francis Flanagan
Assignee:	Merck Sharp and Dohme LLC
Application Number:	US18/630,275
Patent Claims:	1. A pharmaceutical composition comprising: (1) suvorexant in an amorphous form; (2) a concentration-enhancing polymer selected from the group consisting of copovidone, hydroxypropyl cellulose (HPC), hydroxypropyl methyl acetate succinate (HPMCAS), hydroxypropyl methylcellulose (HPMC), hydroxypropyl methyl cellulose phthalate (HPMCP), methyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), and polyvinyl caprolactam-polyvinylacetate-polyethylene glycol graft copolymer; wherein the pharmaceutical composition is prepared by a process comprising hot melt extrusion of a mixture comprising suvorexant and the concentration enhancing polymer and which comprises 5 mg, 10 mg, 15 mg or 20 mg of suvorexant, and wherein the suvorexant is present in a form that contains at least 90 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant. 2. The pharmaceutical composition of claim 1, wherein the concentration-enhancing polymer is selected from the group consisting of copovidone, hydroxypropyl cellulose (HPC), hydroxypropyl methyl acetate succinate (HPMCAS), hydroxypropyl methylcellulose (HPMC), hydroxypropyl methyl cellulose phthalate (HPMCP), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), and polyvinyl caprolactam-polyvinylacetate-polyethylene glycol graft copolymer. 3. A pharmaceutical composition comprising: (1) suvorexant in an amorphous form; (2) a polymer means for enhancing concentration; wherein the pharmaceutical composition is prepared by a process comprising hot melt extrusion of a mixture comprising suvorexant and the polymer means for enhancing concentration and comprises 5 mg, 10 mg, 15 mg or 20 mg of suvorexant. 4. The pharmaceutical composition according to claim 3 comprising: (1) suvorexant in an amorphous form; (2) a polymer means for enhancing concentration, wherein said polymer means is selected from the group consisting of copovidone, hydroxypropyl cellulose (HPC), hydroxypropyl methyl acetate succinate (HPMCAS), hydroxypropyl methylcellulose (HPMC), hydroxypropyl methyl cellulose phthalate (HPMCP), methyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), and polyvinyl caprolactam-polyvinylacetate-polyethylene glycol graft copolymer; and wherein the pharmaceutical composition is prepared by a process comprising hot melt extrusion of a mixture comprising suvorexant and the polymer means for enhancing concentration and comprises 5 mg, 10 mg, 15 mg or 20 mg of suvorexant.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.